title: Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
abstract: It is well known that long-term glucocorticoid treatment causes osteoporosis, but the precise mechanism remains unclear. Recently, osteoprotegerin (OPG) has been identified as a cytokine that inhibits osteoclast differentiation. We have previously demonstrated that serum OPG is suppressed by glucocorticoids. Therefore, the present study was carried out to clarify the interrelationships between OPG and other markers of bone metabolism during glucocorticoid treatment. Thirteen patients (7 men, 6 women; 44.1 +/- 5.9 years old) with chronic glomerulonephritis who were to be treated with glucocorticoids for the first time were chosen for this study. Markers of bone metabolism, including serum OPG, osteocalcin (OC), bone-specific alkaline phosphatase activity (bAP), parathyroid hormone (PTH), tartrate-resistant acid phosphatase (TRAP), and bone mineral density (BMD), were measured before and during the treatment period. Glucocorticoids significantly reduced BMD of the lumbar spine in the 6 month treatment period (p < 0.01). Serum OPG was decreased significantly by glucocorticoids within 2 weeks (p < 0.001), and serum TRAP, a marker of bone resorption, was markedly increased (p < 0.001). On the other hand, there were no remarkable changes in serum PTH. Serum OC and bAP, markers of bone formation, were transiently reduced during the treatment period (p < 0.01). Furthermore, only serum OPG was positively and independently correlated with percentage BMD of age-matched reference (%AMR). These findings imply that glucocorticoid-induced bone loss develops rapidly via enhanced bone resorption and suppressed bone formation. Moreover, the increased bone resorption caused by glucocorticoids may be, at least in part, mediated by inhibition of OPG, not increment of PTH.
authors.affiliation: Department of Nephrology, Jichi Medical School, Tochigi, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sasaki
authors.forename: E
authors.initials: E
authors.lastname: Kusano
authors.forename: Y
authors.initials: Y
authors.lastname: Ando
authors.forename: J
authors.initials: J
authors.lastname: Nemoto
authors.forename: O
authors.initials: O
authors.lastname: Iimura
authors.forename: C
authors.initials: C
authors.lastname: Ito
authors.forename: S
authors.initials: S
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Yano
authors.forename: E
authors.initials: E
authors.lastname: Tsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002908:Chronic Disease; D005260:Female; D005921:Glomerulonephritis / Q000097:blood* / Q000188:drug therapy; D005938:Glucocorticoids / Q000009:adverse effects*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor; D012044:Regression Analysis; D018709:Statistics, Nonparametric
chemical_list: D015415:Biomarkers; D005938:Glucocorticoids; D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human